Physician profile
Jane Jee-Sun Kang
NPI 1174637755
$1,456.01
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $335 · 2022: $161 · 2023: $439 · 2024: $521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $887 · Education: $72.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $887.11 |
| Education | $72.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $403.25 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $232.26 | 2021-2024 | Spravato |
| Alkermes, INC. | $220.46 | 2021-2023 | Vivitrol |
| Otsuka America Pharmaceutical, INC. | $168.66 | 2021-2024 | Rexulti, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $159.80 | 2021-2024 | Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $124.95 | 2021-2024 | Caplyta |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $28.78 | 2024 | Rexulti |
| Axsome Therapeutics, INC. | $26.14 | 2023 | Auvelity |
| Lundbeck LLC | $22.27 | 2021 | |
| Tris Pharma INC | $21.55 | 2024 | Dyanavel Xr |
| Sage Therapeutics, LLC | $19.59 | 2021 | |
| Vanda Pharmaceuticals INC. | $14.50 | 2024 | Hetlioz, Fanapt |
| Idorsia Pharmaceuticals US INC | $13.80 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Kang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.